A number of pharmaceutical companies announced 2021 results, core drugs driven performance growth

Recently, a number of pharmaceutical enterprises announced 2021 performance.According to People’s Daily Health App, core drugs are the key points driving performance growth.Novartis (NOVARTIs) announced its 2021 results on February 2, reporting a combined $8.266 billion contribution to novartis’ growth.In December 2021, it became the only biologic approved for children and adolescents with active tendinitis related arthritis and active juvenile psoriatic arthritis, and it also achieved strong growth after being included in the National Medical insurance list.Sarcurbatol valsartan has become the preferred treatment for patients with heart failure with reduced ejection fraction and retained ejection fraction. Its two indications of reduced ejection fraction, heart failure and hypertension, have been listed in the National Medical insurance catalog, effective from January 2022.Novo Nordisk on February 2, novo Nordisk announced the results of 2021. Victoza’s sales revenue in China in 2021 was 1.544 billion Danish kroner (about 1.592 billion yuan).Novo Nordisk’s current core products are Smiglupeptide, of which the sales revenue of oral preparation Rybelsus was 4.838 billion Danish kroner (approximately usd 769 million), and the sales revenue of subcutaneous preparation Ozempic was 33.705 billion Danish kroner (approximately USD 5.359 billion).Novo Nordisk has seen rapid growth in the weight-loss drug market following the FDA’s approval of Wegovy for its subcutaneous injection.Abbvie:On February 2, AbbVie announced its 2021 results, with revenue of autoimmune diseases reaching us $25.284 billion, accounting for 45% of the total, including sales of Adamuzumab reaching US $20.694 billion in 2021, the annual sales of a single drug exceeding US $20 billion.At the same time, the follow-up autoimmune product line also strongly filled the position, with sales revenue of $2.939 billion for Resizumab and $1.65 billion for upatinib, as double insurance.Abbvie sees oncology as its second largest segment after autoimmune diseases, with Vinecola generating $1.82 billion in 2021 sales, up 36.1% from a year earlier.Gilead sciences announced its 2021 results on February 1 that bitovir, a three-in-one HIV drug, was the company’s core product for growth, with sales of $8.624 billion in 2021, up 19% from a year earlier.Remdesivir sales revenue reached $5.56 billion, up 98%;Cell therapy sales continued to grow rapidly and steadily, rising 43% to $871 million.Aquilenza became the first CAR T-cell therapy to report 5-year survival data for refractory large B-cell lymphoma and demonstrate long-term survival benefits, and was also approved in China for 2021 sales of $690 million, up 23% from last year.Disclaimer: The copyright of this article belongs to the original author. If there is any source error or infringement of your legitimate rights and interests, you can contact us through email, and we will deal with it in time.Email address: jpbl@jp.jiupainews.com

Leave a Reply

Your email address will not be published.